BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

535 related articles for article (PubMed ID: 23341526)

  • 1. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.
    Welsh JW; Komaki R; Amini A; Munsell MF; Unger W; Allen PK; Chang JY; Wefel JS; McGovern SL; Garland LL; Chen SS; Holt J; Liao Z; Brown P; Sulman E; Heymach JV; Kim ES; Stea B
    J Clin Oncol; 2013 Mar; 31(7):895-902. PubMed ID: 23341526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases.
    Lee SM; Lewanski CR; Counsell N; Ottensmeier C; Bates A; Patel N; Wadsworth C; Ngai Y; Hackshaw A; Faivre-Finn C
    J Natl Cancer Inst; 2014 Jul; 106(7):. PubMed ID: 25031274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.
    Magnuson WJ; Lester-Coll NH; Wu AJ; Yang TJ; Lockney NA; Gerber NK; Beal K; Amini A; Patil T; Kavanagh BD; Camidge DR; Braunstein SE; Boreta LC; Balasubramanian SK; Ahluwalia MS; Rana NG; Attia A; Gettinger SN; Contessa JN; Yu JB; Chiang VL
    J Clin Oncol; 2017 Apr; 35(10):1070-1077. PubMed ID: 28113019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial.
    Yang JJ; Zhou C; Huang Y; Feng J; Lu S; Song Y; Huang C; Wu G; Zhang L; Cheng Y; Hu C; Chen G; Zhang L; Liu X; Yan HH; Tan FL; Zhong W; Wu YL
    Lancet Respir Med; 2017 Sep; 5(9):707-716. PubMed ID: 28734822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma.
    Gerber NK; Yamada Y; Rimner A; Shi W; Riely GJ; Beal K; Yu HA; Chan TA; Zhang Z; Wu AJ
    Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):322-9. PubMed ID: 24679729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of whole brain radiation therapy on CSF penetration ability of Icotinib in EGFR-mutated non-small cell lung cancer patients with brain metastases: Results of phase I dose-escalation study.
    Zhou L; He J; Xiong W; Liu Y; Xiang J; Yu Q; Liang M; Zhou X; Ding Z; Huang M; Ren L; Zhu J; Li L; Hou M; Ding L; Tan F; Lu Y
    Lung Cancer; 2016 Jun; 96():93-100. PubMed ID: 27133757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors for brain metastases from non-small cell lung cancer with EGFR mutation: influence of stable extracranial disease and erlotinib therapy.
    Sekine A; Satoh H; Iwasawa T; Tamura K; Hayashihara K; Saito T; Kato T; Arai M; Okudela K; Ohashi K; Ogura T
    Med Oncol; 2014 Oct; 31(10):228. PubMed ID: 25208818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma.
    Iuchi T; Shingyoji M; Sakaida T; Hatano K; Nagano O; Itakura M; Kageyama H; Yokoi S; Hasegawa Y; Kawasaki K; Iizasa T
    Lung Cancer; 2013 Nov; 82(2):282-7. PubMed ID: 24021541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320.
    Sperduto PW; Wang M; Robins HI; Schell MC; Werner-Wasik M; Komaki R; Souhami L; Buyyounouski MK; Khuntia D; Demas W; Shah SA; Nedzi LA; Perry G; Suh JH; Mehta MP
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1312-8. PubMed ID: 23391814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of whole brain radiotherapy with or without erlotinib in patients with multiple brain metastases from lung adenocarcinoma.
    Zhuang H; Yuan Z; Wang J; Zhao L; Pang Q; Wang P
    Drug Des Devel Ther; 2013; 7():1179-86. PubMed ID: 24133369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gefitinib and erlotinib for non-small cell lung cancer patients who fail to respond to radiotherapy for brain metastases.
    Song Z; Zhang Y
    J Clin Neurosci; 2014 Apr; 21(4):591-5. PubMed ID: 24256883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small-cell lung cancer.
    Lind JS; Lagerwaard FJ; Smit EF; Senan S
    Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1391-6. PubMed ID: 19289264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population.
    Ma S; Xu Y; Deng Q; Yu X
    Lung Cancer; 2009 Aug; 65(2):198-203. PubMed ID: 19091441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer.
    Komaki R; Allen PK; Wei X; Blumenschein GR; Tang X; Lee JJ; Welsh JW; Wistuba II; Liu DD; Hong WK
    Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):317-24. PubMed ID: 25968826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of icotinib and whole-brain radiotherapy in Chinese patients with brain metastases from non-small cell lung cancer.
    Fan Y; Huang Z; Fang L; Miao L; Gong L; Yu H; Yang H; Lei T; Mao W
    Cancer Chemother Pharmacol; 2015 Sep; 76(3):517-23. PubMed ID: 26148750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803).
    Wu YL; Zhou C; Cheng Y; Lu S; Chen GY; Huang C; Huang YS; Yan HH; Ren S; Liu Y; Yang JJ
    Ann Oncol; 2013 Apr; 24(4):993-9. PubMed ID: 23129122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Whole-brain radiotherapy with and without concurrent erlotinib in NSCLC with brain metastases: a multicenter, open-label, randomized, controlled phase III trial.
    Yang Z; Zhang Y; Li R; Yisikandaer A; Ren B; Sun J; Li J; Chen L; Zhao R; Zhang J; Xia X; Liao Z; Carbone DP
    Neuro Oncol; 2021 Jun; 23(6):967-978. PubMed ID: 33331923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gefitinib alone or with concomitant whole brain radiotherapy for patients with brain metastasis from non-small-cell lung cancer: a retrospective study.
    Zeng YD; Zhang L; Liao H; Liang Y; Xu F; Liu JL; Dinglin XX; Chen LK
    Asian Pac J Cancer Prev; 2012; 13(3):909-14. PubMed ID: 22631670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer.
    Iyengar P; Kavanagh BD; Wardak Z; Smith I; Ahn C; Gerber DE; Dowell J; Hughes R; Abdulrahman R; Camidge DR; Gaspar LE; Doebele RC; Bunn PA; Choy H; Timmerman R
    J Clin Oncol; 2014 Dec; 32(34):3824-30. PubMed ID: 25349291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. From clinical trials to clinical practice: predictors of response to erlotinib in advanced non-small cell lung cancer patients pretreated with chemotherapy.
    Mazzoni F; Rotella V; Pratesi N; Boni L; Simi L; Orlando C; Comin CE; Maddau C; Di Costanzo F
    Tumori; 2011; 97(2):160-5. PubMed ID: 21617709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.